Factors affecting the disease severity of COVID-19 patients in an emergency setting

SAMUEL BUNGARAN PARTAH, SAUD MANALU, ELCHEA LEONARD, CARENNIA PARAMITA, MARSHELL TENDERAN

Background

Coronavirus disease 2019 (COVID-19) is a new type of pneumonia that was first discovered in December 2019 [1]. This disease is highly contagious with a fast rate of spread [2]. Since it was first announced by the World Health Organization (WHO), more than 169 million people have been infected, with the death toll reaching more than 3.5 million. In Indonesia, the number of people infected with COVID-19 has reached 1.8 million, with the number of deaths amounting to more than 50 thousand people (approx. 18.4%) [3]. Indonesia is the fourth most populous country in the world with lower-middle income levels, which currently has the highest confirmed cases and deaths from COVID-19 in Southeast Asia, which also ranks second in Asia after India [4].

Currently, the world is still trying to control the spread of COVID-19 through lockdowns in several regions and mass vaccination programmes [5]. However, another problem has arisen with a new variant of the virus with a more robust transmission ability and infection power than the original variant [6, 7]. The emergence of new variants is caused by a mutation process, which has caused the second wave of infection that is happening at present [8]. A study in Ontario, Canada, found that new variants, or Variants of Concern (VOCs), accounted for 67% of all cases of SARS-CoV-2 infections in that country. Compared to the previous variant, VOCs were associated with an increased risk of hospitalisation of up to 63%, an increased risk of intensive care unit (ICU) admission up to 103% and an increased risk of death from COVID-19 by up to 56% [9]. Regarding the spread of VOCs infection, Indonesia experienced an increase in the number of cases per day by around 5,446 compared to the previous week of approximately 3,557 cases per day, based on surveillance data on 26 May 2021 [10].

In addition to the number of cases that are continuing to increase, the incidence rate of mortality in Indonesia is still relatively high compared to the rest of the world and other countries in Asia [11]. Besides the significant increase in cases, the long-term impact of COVID-19 is also worrying. Previously, there was a misconception that all COVID-19 patients would recover in two weeks. However, there are symptoms that are long lasting, even if the patients experienced mild symptoms or was not admitted to hospital. This condition is called long COVID [12].

Researchers continue to look for innovations in handling COVID-19, including how to predict the deterioration of COVID-19 and further possible events [13]. It was reported that the National Early Warning Score 2 (NEWS2) can be applied as a sensitive method for predicting the worsening condition of COVID-19 patients. NEWS2 shows superior accuracy compared to COVID-GRAM in estimating the likelihood of patients’ conditions becoming critical [14]. Therefore, this study aims to determine factors affecting the disease severity of COVID-19 patients in emergency settings based on NEWS2.

Objectives

The aim of this study was to analyse factors affecting the disease severity of COVID-19 patients in an emergency setting.

Results

The results showed mild severity of COVID-19 (84.4%) followed by moderate (9.9%) and severe COVID-19 (5.7%). We also found that age (p = 0.003), hypertension (p = 0.095), diabetes mellitus (p = 0.191), atherosclerosis (p = 0.048), renal function (p = 0.191), diabetes mellitus (p = 0.007) were eligible for multivariate analysis. Further analysis showed that age (p = 0.038) and diabetes mellitus (p = 0.034) are the most significant factors related to the severity of the disease.

Conclusions

Age and diabetes mellitus are significant factors contributing to the severity of COVID-19 in an emergency setting. COVID-19 pandemic, severity of illness, health correlates.
Material and methods

Study design

This analytical study was conducted with a cross-sectional design.

Population and sample

The total population included confirmed COVID-19 patients who presented to the emergency room at UKRIDA Hospital (West Jakarta, DKI Jakarta) from January to May 2021. Non-probability consecutive sampling was used to collect the participants. A total of 262 participants were eligible and became the sample of this study. Total samples were measured using the slovin formula, with a 95% confidence interval. Participants included in this study were confirmed COVID-19 patients aged more than 18 years who presented to the emergency room between January and May 2021. On the other hand, we excluded participants who were confirmed COVID-19 but had been fully or partially vaccinated, had congenital defects such as a heart congenital anomaly or had a history of being infected by COVID-19.

Study instrument

Data collection was carried out using secondary data collected from the Medical Record Installation of UKRIDA Hospital from January to May 2021. There were ten variables observed in this study, such as the severity of COVID-19 measured by the New Early Warning Score 2 (NEWS2), classified into mild: low (score 1–4), moderate: medium (score 5 and 6 or score of 3 in any individual parameter) and severe: high (score > 7); gender (male or female); age divided into 18–45 years and > 45 years; history of hypertension; history of diabetes mellitus; history of atherosclerosis, which is defined as patients who have experienced a heart attack or stroke confirmed by medical doctors; onset to admission (O–A) interval, which is calculated as time between the onset of the first symptoms (fever, cough, shortness of breath/dyspnoea, flu, diarrhoea, anosmia and ageusia) and patient admissions to the emergency ward, categorised by less than seven days and more than seven days; haemoglobin (Hb) level divided to anaemia, defined as Hb < 13 gr/dl for male or Hb < 12 gr/dl for female, and normal, defined as Hb ≥ 13 gr/dl for male or Hb ≥ 12 gr/dl for female; renal function tests divided to impaired, defined as elevation of creatinine level more than 1-fold baseline, and non-impaired, defined as normal to elevation 1-fold normal of creatinine level; and liver enzymes tests divided to impaired, defined as elevation of aspartate transaminase (AST) and/or alanine transaminase (ALT) level more than 1-fold normal of AST and/or ALT level.

Data analysis

Data was analysed using SPSS software. Descriptive analysis was conducted to determine the characteristics of all participants included in the study. Following the prior analysis, a bivariate analysis with the Chi square and other alternatives was performed to analyse the relationship between each factor. Factors with a p-value < 0.25 were considered statistically significant and would be further analysed with multinomial logistic regression to determine the most dominant influence among all the deterioration risks of COVID-19.

Ethical approval

Approval for this study was obtained from the Medical and Health Research Ethics Committee, Faculty of Medicine and Health Sciences, Krida Wacana Christian University, Indonesia (approval No: 1114/SKE-IM/UKKW/FKIK/KE/VII/2021).

Results

| Table 1. Subject characteristics |
|-----------------|-----------------|-----------------|-----------------|
| Characteristics  | Category         | Frequency       | Percentage      |
| Age             | > 45 years       | 168             | 64.1%           |
|                 | 18–45 years      | 94              | 35.9%           |
| Gender          | male             | 132             | 50.4%           |
|                 | female           | 130             | 49.6%           |
| COVID-19 severity | mild             | 221             | 84.4%           |
|                 | moderate         | 26              | 9.9%            |
|                 | severe           | 15              | 5.7%            |
| Hypertension    | yes              | 90              | 34.4%           |
|                 | no               | 172             | 65.6%           |
| Diabetes mellitus | yes             | 37              | 14.1%           |
|                 | no               | 225             | 85.9%           |
| Atherosclerosis | yes              | 38              | 14.5%           |
|                 | no               | 224             | 85.5%           |
| Onset to admission interval | > 7 days ≤ 7 days | 39              | 14.9%           |
|                 | < 7 days         | 223             | 85.1%           |
| Haemoglobin concentration | anaemia | 53              | 20.2%           |
|                 | normal           | 209             | 79.8%           |
| Renal function  | impaired         | 7               | 2.7%            |
|                 | non-impaired     | 255             | 97.3%           |
| Liver function  | impaired         | 27              | 10.3%           |
|                 | non-impaired     | 235             | 89.7%           |

| Table 2. Independent factors analysed by bivariate analysis |
|-----------------|-----------------|-----------------|-----------------|
| Variable        | Severity         | Mild | Moderate | Severe | P      |
| Age             | > 45 years       | 132  | 23      | 13     | 0.003* |
|                 | 18–45 years      | 89   | 3       | 2      |        |
| Gender          | male             | 110  | 14      | 8      | 0.900* |
|                 | female           | 111  | 12      | 7      |        |
| Hypertension    | yes              | 70   | 12      | 8      | 0.095* |
|                 | no               | 151  | 14      | 7      |        |
Table 2. Independent factors analysed by bivariate analysis

| Variable               | Severity | Mild | %   | Moderate | %   | Severe | %   | p      |
|------------------------|----------|------|-----|----------|-----|--------|-----|--------|
|                        |          | n    |     | n        |     | n      |     |        |
| Diabetes mellitus      | yes      | 29   | 11.1| 2        | 0.8| 6      | 2.3| 0.191* |
|                        | no       | 192  | 73.3| 24       | 9.2| 9      | 3.4|        |
| Atherosclerosis        | yes      | 26   | 9.9 | 8        | 3.1| 4      | 1.5| 0.004* |
|                        | no       | 195  | 74.4| 18       | 6.9| 11     | 4.2|        |
| Onset to admission interval | > 7 days | 28   | 10.7| 6        | 2.3| 5      | 1.9| 0.016* |
|                        | ≤ 7 days | 193  | 73.7| 20       | 7.6| 10     | 3.8|        |
| Haemoglobin concentration | anaemia  | 42   | 16.0| 8        | 3.1| 3      | 1.1| 0.369* |
|                        | normal   | 179  | 68.3| 18       | 6.9| 12     | 4.6|        |
| Renal function         | impaired | 4    | 1.5 | 2        | 0.8| 1      | 0.4| 0.048* |
|                        | non-impaired | 217 | 82.8| 24       | 9.2| 14     | 5.3|        |
| Liver function         | impaired | 18   | 6.9 | 5        | 1.9| 4      | 1.5| 0.007* |
|                        | non-impaired | 203 | 77.5| 21       | 8.0| 11     | 4.2|        |

* Chi-square test, † Mann-Whitney test.

Table 3. Variables affecting the disease severity of COVID-19 patients according to the results of multinomial logistic regression

| Variable               | Category | OR (95% CI) | Mild to severe | Moderate to severe | p      |
|------------------------|----------|-------------|----------------|-------------------|--------|
| Age                    | > 45 years old (Ref) | 1 | 1 | 0.038 |
|                        | 18–45 years old | 2.79 (0.54–14.37) | 0.69 (0.08–5.40) | 0.980 |
| Hypertension           | yes (Ref) | 1 | 1 | 0.980 |
|                        | No       | 0.92 (0.26–3.24) | 0.86 (0.19–3.77) | 0.034 |
| Diabetes mellitus      | yes (Ref) | 1 | 1 | 0.034 |
|                        | No       | 2.76 (0.76–10.05) | 10.62 (1.53–73.59) | 0.124 |
| Atherosclerosis        | yes (Ref) | 1 | 1 | 0.349 |
|                        | No       | 1.73 (0.43–6.89) | 0.60 (0.12–3.01) | 0.580 |
| Onset to admission interval | ≥ 7 days | 2.03 (0.57–7.24) | 1.07 (0.22–5.08) | 0.007* |
|                        | < 7 days | 1 | 1 | 0.174 |
| Renal function         | impaired (Ref) | 1 | 1 | 0.05 |
|                        | non-impaired | 1.97 (0.18–20.77) | 0.73 (0.05–9.97) | 0.89–13.65) | 1.82 (0.34–9.59) |
| Liver function         | impaired (Ref) | 1 | 1 | 0.007* |
|                        | non-impaired | 3.49 (0.89–13.65) | 1.82 (0.34–9.59) | 0.007* |

Ref – reference category, CI – confident interval.

Discussion

In this study, we found that age has a significant association with COVID-19 severity (p = 0.038). Several studies have also shown that age plays a significant role [15–18]. This condition was due to alterations in the quantity or quality of the immune system, which affects the response of immune cells and mediators in peripheral tissues. These changes determine not only the susceptibility to infection but also disease progression, clinical risk in the future and the response to vaccination [19]. The other factor leading to the elderly being more likely to have poor prognosis is that most of them have underlying conditions, like hypertension, diabetes, lung disease or heart disease [20]. Global statistical data indicates different case fatality rates among genders [21]. Men tended to develop more serious cases compared to women, according to the clinical classification of severity. The total number of deceased male patients is 2.4 times higher than that of females [22]. The ef-
fect of hypertension on critical COVID-19 patients was explored, and it was revealed that patients with hypertension were associated with a significantly increased risk of developing a critical illness (OR: 2.92; 95% CI: 2.26–3.77; and p < 0.001) [23]. Xiong et al. [24] also found that COVID-19 patients with hypertension had a greater chance of ICU admission (p < 0.001), mechanical ventilation (p < 0.001) and death (p = 0.012). We also found that people with diabetes mellitus were more likely to develop severe COVID-19 (p = 0.34). Guo et al. [25] reported that plasma glucose levels and diabetes are predicting factors for unfavourable clinical outcomes (morbidity and mortality) in COVID-19 patients (p = 0.03). The pathophysiology of COVID-19 and diabetes mellitus might be due to the reduced macrophage function. There are also other factors, such as chronic hyperglycaemia and inflammation, considered as possible reasons for an abnormal and ineffective immune response [26, 27]. Bouhanick et al. [28] also found that diabetes and age were associated with the occurrence of severe condition. A meta-analysis done by Palaiodimos et al. showed that the likelihood of death seems to be higher in diabetic patients hospitalised with COVID-19 compared to non-diabetic patients [29]. A meta-analysis done by de Almeida-Pititto et al. showed that diabetes, hypertension and especially cardiovascular disease are detrimental risk factors for severity and mortality in COVID-19 patients [30]. Atherosclerotic progression can lead to a severe inflammatory response and plays a role in the massive plasmatic concentration of cytokines [31]. COVID-19 patients with pre-existing cardiovascular issues have a higher risk of severe disease and death. In addition to that, the COVID 19 infection itself has been associated with multiple direct and indirect cardiovascular complications [32]. In a study by Alaa et al. [33] in England, the timing of hospital admission was associated with mortality in patients with COVID-19. The onset to admission interval ranged between 3 and 10.4 days, with the longest delay being in the 20–60 year age group [34]. Research carried out by Peng et al. showed that there was no association between the O-A interval and mortality or the length of hospital stay for severe-to-critical patients [35]. A cohort study in China show that in COVID-19 patients with anaemia, there is an elevation of C-reactive protein, procalcitonin and creatinine levels, which are related to severe COVID-19 [36]. Anaemia can be used as a factor that predicts poor prognosis in COVID-19 patients, including ventilator need and ICU admission or death [37]. However, several studies in Italy [38] and China [39] found no relationship between anaemia and severity of COVID-19. Several studies showed that poor renal function was related to poor COVID-19 outcome [40–42]. The association between renal function and COVID-19 can be addressed in two reciprocal ways: the effect of decreasing renal function with the severity of COVID-19, and the effect of COVID-19 with the renal function or renal disease. In this study, they mainly discussed the effect of decreasing e-GFR (decrease of renal function) with the severity of COVID-19 [40]. Krishna et al. [43] showed that patients with liver enzyme elevations and the presence of a comorbidity were at higher risk of death (OR: 5.314; 95% CI: 2.278–12.393). Ahmed et al. [44] also found that the relation of AST, ALT and total bilirubin was related with the severity of COVID-19. Leulseged et al. [45] observed that the increment of SGOT level (≥ 41 IU/L) was associated with a 3.358 times increased risk of having severe disease compared to those with normal SGOT level range (p < 0.0001).

Limitations of the study

We realise that as we were using secondary data from medical records, the collected data might be incomplete. Some of the data about the comorbid histories that were documented based on patient’s information might be subjective. We also realise that there might be other factors that possibly related to the severity of COVID-19 but unfortunately those factors were not documented in the medical record.

Conclusions

We found that age and diabetes mellitus are significant factors contributing to the severity of COVID-19 in an emergency setting.

Acknowledgements. We would like to show our gratitude to UKRIDA Hospital for their support in this study.

References

1. Wang C, Wang Z, Wang G. COVID-19 in early 2021: current status and looking forward. Sig Transduct Target Ther 2021; 6(114), doi: 10.1038/s41392-021-00527-1.
2. Wu D, Wu T, Liu Q, et al. The SARS-CoV-2 outbreak: What we know. Int J Infect Dis 2020; 94: 44–48, doi: 10.1016/j.ijid.2020.03.004.
3. Weekly epidemiological update on COVID-19 – 1 June 2021 [Internet]. Who.int 2022 [cited 4.06.2021]. Available from URL: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-june-2021.
4. Surendra H, Elayzar IR, Djaafara BA, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: a hospital-based retrospective cohort study. Lancet Reg Health West Pac 2021; 9: 100108, doi: 10.1016/j.lanwpc.2021.100108.
5. Ranjan R, Sharma A, Verma M. Characterization of the Second Wave of COVID-19 in India. Current Science 2021; 121(1): 85–93.
6. Chen J, Wang R, Wang M, et al. Mutations Strengthened SARS-CoV-2 Infectivity. J Mol Biol 2020; 432(19): 5212–5226, doi: 10.1016/j.jmb.2020.07.009.
7. Davies NG, Davies NG, Abbott S, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 2021; 372(6538): eab3035, doi: 10.1126/science.abg3035.
8. Vallverdu I, Herna S, Iftimie S, et al. First and second waves of coronavirus disease-19: a comparative study in hospitalized patients in Reus, Spain. Plos ONE 2021; 16(3): e0248029, doi: 10.1371/journal.pone.0248029.
9. Tuite AR, Fisman DN, Odutayo A, et al. COVID-19 hospitalizations, ICU admissions and deaths associated with the new variants of concern. Science Briefs of the Ontario COVID19 Science Advisory Table 2021; 1(18), doi: 10.47326/locast.2021.02.18.1.0.
10. Coronavirus disease 2019 (COVID 19) Situation Report-56. Cdn.who.int 2022 [cited 4.06.2021]. Available from URL: https://cdn.who.int/media/docs/default-source/searo/indonesia/covid19/external-situation-report-56_26-may-2021.pdf?sfvrsn=b05d7bb5_5.
11. Susanto N. Differences of confirmatory case, mortality rate and incident mortality of COVID-19 in Indonesia, Asia and WHO online data case study. Jurnal Ilmu Kesihatan Masyarakat 2021; 12(1): 50–59, doi: 10.26553/jikkm.2021.12.1.50-59.
12. Al-Jahdhami I, Al-Naamani K, Al-Mawali A. The Post-acute COVID-19 Syndrome (Long COVID). Oman Med J 2021; 36(1): e220, doi: 10.5001/omj.2021.91.
13. Baker AKF, Hanrahnt AAT, Loef LBS van der, et al. National Early Warning Score 2 (NEWS2) to identify inpatient COVID-19 deterioration: a retrospective analysis. Clin Med (Lond) 2021; 21(2): 84–89, doi: 10.7861/clinmed.2020-0688.
14. Vittorio G, Anna DS, Francesco G, et al. National Early Warning Score 2 (NEWS2) better predicts critical Coronavirus Disease 2019 (COVID-19) illness than COVID-GRAM, a multi-centre study. *Infection* 2021; 49(5): 1033–1038, doi: 10.1007/s15010-021-01620-x.

15. Luo H, Liu S, Wang Y, et al. Age differences in clinical features and outcomes in patients with COVID-19, Jiangsu, China: A retrospective, multicentre cohort study. *BMJ Open* 2020; 10: e039987, doi: 10.1136/bmjopen-2020-039887.

16. Yi P, Yang X, Ding C, et al. Risk factors and clinical features of deterioration in COVID-19 patients in Zhejiang, China: a single-centre, retrospective study. *BMJ Infect Dis* 2020; 20(1): 943, doi: 10.1186/s12879-020-00682-4.

17. O’Driscoll M, Ribeiro Dos Santos G, Wang L, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature* 2021; 590(7844): 140–145, doi: 10.1038/s41586-020-2918-0.

18. Ho JSY, Fernando DI, Chan MY, et al. Obesity in COVID-19: a systematic review and meta-analysis. *Ann Acad Med Singapore* 2020; 49(12): 996–1008.

19. Bajaj V, Gadi N, Spihlman AP, et al. Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? *Front Physiol* 2021; 11: 1–23.

20. Crimmins EM. Age-Related Vulnerability to Coronavirus Disease 2019 (COVID-19): Biological, Contextual, and Policy-Related Factors. *Public Policy Aging Rep* 2020; 30(4): 142–146.

21. Dehingia N, Raj A. Sex differences in COVID-19 case fatality: do we know enough? *Lancet Glob Heal* 2021; 9(1): e14–e45, doi: 10.1016/s2214-109x(20)30464-2.

22. Jin JM, Bai P, He W, et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. *Front Public Heal* 2020; 8: 1–6.

23. Du Y, Zhou N, Zha W, et al. Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: A meta-analysis. *Nutr Metab Cardiovasc Dis* 2021; 31(3): 745–755, doi: 10.1016/j.numecd.2020.12.009.

24. Xiong TY, Huang FY, Liu Q, et al. Hypertension is a risk factor for adverse outcomes in patients with coronavirus disease 2019: a cohort study. *Ann Med* 2020; 52(7): 361–366, doi: 10.1080/07853890.2020.1802059.

25. Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes Metab Res Rev* 2020; 36(7): 1–9.

26. Iacobellis G. COVID-19 and diabetes: Can DPP4 inhibition play a role? *Diabetes Res Clin Pract* 2020; 162: 108125, doi: 10.1016/j.diabres.2020.108125.

27. Huang I, Lim M, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – a systematic review, meta-analysis, and meta-regression. *Diabetes Metab Syndr* 2020; 14(4): 395–403, doi: 10.1016/j.dsx.2020.04.018.

28. Bouhanick B, Cracowski J-L, Faille J-L. Diabetes and COVID-19. *Therapie* 2020; 75(4): 327–333, doi: 10.1016/j.therap.2020.05.006.

29. Palaiodimos L, Chamorro-Pareja N, Karamanis D, et al. Diabetes is associated with increased risk for in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis comprising 18,506 patients. *Hormones* 2021; 20(2): 305–314.

30. De Almeida-Pititto B, Dualib PM, Zajdenverg L, et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. *Diabetol Metab Syndr* 2020; 12(1): 1–12, doi: 10.1186/s13098-020-00586-4.

31. Vinciguerra M, Romiti S, Fattouch K, et al. Atherosclerosis as Pathogenetic Substrate for Sars-Cov2 Cytokine Storm. *J Clin Med* 2020; 9(7): 2095.

32. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. *J Am Coll Cardiol* 2020; 75(18): 2352–2371.

33. Alaa A, Qian Z, Rashbass J, et al. Retrospective cohort study of admission timing and mortality following COVID-19 infection in England. *BMJ Open* 2020; 10(11): e042712.

34. Faes C, Abrams S, Beckhoven D van, et al. Time between symptom onset, hospitalisation and recovery or death: Statistical analysis of belgium COVID-19 patients. *Int J Environ Res Public Health* 2020; 17(20): 1–18.

35. Peng L, Lv Q-Q, Yang F, et al. The interval between onset and admission predicts disease progression in COVID-19 patients. *Ann Transl Med* 2020; 9(3): 213–213.

36. Tao Z, Xu J, Chen W, et al. Anemia is associated with severe illness in COVID-19: a retrospective cohort study. *J Med Virol* 2021; 93(3): 1478–1488.

37. Faghii Dinevari M, Somi MH, Sadeghi Majd E, et al. Anemia predicts poor outcomes of COVID-19 in hospitalized patients: a prospective study in Iran. *BMJ Infect Dis* 2021; 21(1): 1–7.

38. Cecconi M, Piovani D, Brunetta E, et al. Early predictors of clinical deterioration in a cohort of 239 patients hospitalized for COVID-19 infection in Lombardy, Italy. *J Clin Med* 2020; 9(5): 1–16.

39. Yang X, Yu Y, Xu J, et al. Clinical Course and outcomes of critically ill patients with COVID19 in Wuhan China. *Lancet Respir Med* 2020; 8(5): 475–481.

40. Trabulus S, Karaca C, Balkan II, et al. Clinical kidney function on admission predicts in-hospital mortality in COVID-19. *PLoS One* 2020; 5: 1–14, doi: 10.1371/journal.pone.0238680.

41. Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney Int* 2020; 97(5): 829–838.

42. Uribarri A, Núñez-Gil U, Aparisi A, et al. Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry. *J Nephrol* 2020; 33(4): 737–745, doi: 10.1007/s40620-020-00790-5.

43. Krishnasamy N, Rajendran K, Barua P, et al. Elevated Liver Enzymes along with Comorbidity Is a High Risk Factor for COVID-19 Mortality: A South Indian Study on 1,512 Patients. *J Clin Transl Hepatol* 2020; 5(1): 1–4.

44. Ahmed M, Umar M, Sufyan A, et al. Liver Function Tests; A Marker of Severity in COVID-19 Patients. *Austin Hepatol* 2020; 5(1): 1–4.

45. Leulseged TW, Hassen IS, Ayele BT, et al. Laboratory biomarkers of COVID-19 disease severity and outcome: findings from a developing country. *PLoS One* 2021; 16: 1–13, doi: 10.1371/journal.pone.0246087.

**Tables:** 3  
**Figures:** 0  
**References:** 45

---

**Address for correspondence:**  
Samuel Bungaran Partahi Saud Manalu, MD  
Department of Medicine  
UKRIDA Hospital  
Jl. Arjuna Utara No.145, RT.6/RW.2, Duri Kepa, Kec. Kb. Jeruk, Kota Jakarta Barat, 11510 DKI Jakarta  
Indonesia  
Tel.: +62 81311400923  
E-mail: samuel.manalu.4th@gmail.com